The existing partnership is in the field of chronic obstructive pulmonary disease (COPD).
Under the extended deal, the parties will set up a second team of scientists from across the world for discovering novel therapeutic concepts to treat of psychiatric diseases.
Early career neuroscientists from global academic institutions are invited to submit original project proposals that evaluate the complex circuit biology at the interface between projection neurons, interneurons and non-neuronal cells to generate novel therapeutic concepts.
A new research group will be formed within BioMed X’s open innovation lab, which is part of the life science campus of the University of Heidelberg in Germany.
BioMed X will recruit members for the new research group. It will operate the innovation center and allow access to the Heidelberg scientific community and research facilities.
BioMed X founder and managing director Christian Tidona said: "We are excited about Boehringer Ingelheim’s decision to double their commitment after such a short period of time.
"It clearly indicates that our new model is perceived by the pharmaceutical industry as a truly promising external innovation tool."
Image: A second team of scientists from across the world will discover novel therapeutic concepts for the treatment of psychiatric diseases. Photo: courtesy of Boehringer Ingelheim.